- Viracta Therapeutics Inc To Host R&D Day TranscriptOct 04, 2023
- Viracta Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Viracta Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Viracta Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Viracta Therapeutics Inc To Discuss Nana-val For The Treatment Of Advanced Epstein-Barr Virus-Positive Solid Tumors Call TranscriptApr 27, 2022
- Sunesis Pharmaceuticals, Inc., Viracta Therapeutics, Inc. - M&A Call TranscriptNov 30, 2020
- Q3 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptNov 16, 2020Earnings
- Q2 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptAug 11, 2020Earnings
- Q1 2020 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020Earnings
- Q4 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMar 10, 2020Earnings
- Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale TranscriptNov 13, 2019
- Q3 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptNov 12, 2019Earnings
- Q2 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019Earnings
- Q1 2019 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2019Earnings
- Sunesis Pharmaceuticals Inc at Oppenheimer Healthcare Conference TranscriptMar 19, 2019
- Q4 2018 Sunesis Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2019Earnings
Viracta Therapeutics Inc at Jefferies Healthcare Conference Transcript
I think we're good. Good evening, everyone, and welcome to the 2023 Jefferies Global Healthcare Conference. My name is Shreya Chowdhry from the Jefferies investment banking team, and it's my great pleasure to introduce to you today, the CEO and President of Viracta Therapeutics, Mark Rothera.
Good afternoon, and thank you very much to Jefferies for the invitation to speak at the conference today. Viracta was founded in 2015, and it's been a public company since 2021. And our mission is to treat and prevent virus-associated cancer. During the course of the presentation, I may make some forward-looking statements.
So, really for today's presentation, my focus is going to be on Nana-val, which is our lead clinical stage program, which is focused on treating EBV-associated cancers, Epstein-Barr virus associated cancers. And this lead program, Nana-val, is an all-oral combination of nanatinostat, which is an HDAC inhibitor that is being used in this purpose
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)